Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
9
×
biotech
boston blog main
indiana blog main
indiana top stories
9
×
life sciences
national blog main
raleigh-durham blog main
raleigh-durham top stories
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
national
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
cancer
clinical trials
fda
glaxosmithkline
pfizer
astrazeneca
bristol-myers squibb
eli lilly
merck
novartis
regeneron pharmaceuticals
abbvie
What
roundup
bio
drug
new
biotech
buy
cholesterol
conference
days
drugs
fda
news
opioid
won
abbvie’s
according
acquisitions
acute
addresses
advantages
akcea
alliance
annual
approval
ash
august
bar
barbecuing
barcelona
biggest
brings
bristol
build
busy
calls
camping
cancer
cardiologist
cases
causes
Language
unset
9
×
Current search:
amgen
×
unset
×
" indiana top stories "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
4 years ago
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More